The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial.Methods In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period. Eligible patients were aged 25-75 years, had idiopathic Parkinson's disease as measured by Queen Square Brain Bank criteria, were on dopaminergic treatment with wearing-off effects, and were at Hoehn and Yahr stage 2·5 or less when on treatment. Randomisation was by web-based randomisation with a two strata block design according to disease severity. Patients and investigators were masked to treatment allocation. The primary outcome was the adjusted difference in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale (part 3) in the practically defined off-medication state at 60 weeks. All efficacy analyses were based on a modified intention-to-treat principle, which included all patients who completed any post-randomisation follow-up assessments. The study is registered at ClinicalTrials.gov (NCT01971242) and is completed.Findings Between June 18, 2014, and March 13, 2015, 62 patients were enrolled and randomly assigned, 32 to exenatide and 30 to placebo. Our primary analysis included 31 patients in the exenatide group and 29 patients in the placebo group. At 60 weeks, off-medication scores on part 3 of the MDS-UPDRS had improved by 1·0 points (95% CI -2·6 to 0·7) in the exenatide group and worsened by 2·1 points (-0·6 to 4·8) in the placebo group, an adjusted mean difference of -3·5 points (-6·7 to -0·3; p=0·0318). Injection site reactions and gastrointestinal symptoms were common adverse events in both groups. Six serious adverse events occurred in the exenatide group and two in the placebo group, although none in either group were judged to be related to the study interventions.Interpretation Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials.Funding Michael J Fox Foundation for Parkinson's Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with exenatide or lixisenatide for 1 year produced a modest but positive effect on Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores in people with recently diagnosed Parkinson’s disease (15, 53).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This discrepancy may reflect differences in the neuroprotective mechanisms of semaglutide and tirzepatide vs earlier GLP-1RAs, such as exenatide, liraglutide, and lixisenatide, which have demonstrated favorable clinical benefits in early-stage Parkinson disease.33,50”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In Parkinson's disease, phase II trials have shown that GLP-1 RAs such as exenatide and lixisenatide improve motor activity compared to placebo,53,54 and liraglutide has shown improvements in non-motor symptoms, mobility, and quality of life.55”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [142]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple GLP-1 medicines, including exenatide (15), liraglutide (16), semaglutide (17, 18), and tirzepatide (19), reduce plasma CRP levels in people living with T2D and/or obesity.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Moreover, GLP-1 receptors interact with various neurotransmitter systems such as serotonin, dopamine, and glutamate, which are essential for mood regulation and may contribute to the onset of depression and other psychological disorders [82].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [82]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [142]
Experimental — accuracy not yet measuredIn the citing paper
“exenatide, administered at the dose approved for type 2 diabetes treatment, crosses the BBB in appreciable quantities and improves the motor and cognitive function of PD patients.”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [616]
In the citing paper
“This study provides in vivo evidence that “beta-cell rest” can at least temporarily allow insulin secretory capacity recovery, and in vitro studies examining the effect of diazoxide on diabetic human islets produced similar findings.177”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., & Whitton, P. S. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.07.004 · Cited by 32
RetractedHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Self-citationSystematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R. L., Patel, S., Rick, C., Gray, R. G., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R. A., Feigin, P. D., Jankovic, J. J., Lang, A. E., Langston, J. W., Melamed, E., Poewe, W. H., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 902
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 864
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M. R., Reske, S. N., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Rémy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 831
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645
Cited by
Sorted by citations
Items 701–800 of 887
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., Koehler, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522509 · Cited by 2
The Evolving Landscape of Parkinson's Disease Research: Current Challenges and Future OutlookPreprint
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-fp9nj · Cited by 1
Development of disease-modifying drugs for Parkinson’s disease. Is it a tough road?
Nagai, M. (2023) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22129 · Cited by 1
Vijiaratnam, N., Girges, C., Athauda, D. S., King, A., Auld, G., McComish, R., Chowdhury, K., Skene, S. S., Maclagan, K., Chaudhuri, К. R., et al. (2024) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.14191 · Cited by 1
Self-citationImmunotherapy for Neurodegenerative Movement Disorders
Mosley, R. L., Saleh, M., & Olson, K. E. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_52 · Cited by 1
Wahba, A. S., Mohamad, H. E., Abo–Elmatty, D. M., Mesbah, N. M., Wahba, N. S., Azzazy, A. S. E., & Sakr, A. T. (2025) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000835 · Cited by 1
Metabolic Syndrome and Parkinson’s Disease: Two Villains Join Forces
Udovin, L., Bordet, S., Chevalier, G., Barbar, H., Losada, M. E. O., Capani, F., & Perez‐Lloret, S. (2025) · Brain Sciences · doi:10.3390/brainsci15070706 · Cited by 1
“The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide, used in Diabetes Mellitus Type 2, has shown promising results for motor symptoms in PD clinical trials [20].”
Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects
Kim, K. S., Park, J. S., & Choi, H. J. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448320.160 · Cited by 2
“Their effectiveness in addressing inflammation might be the reason for GLP-1RA effects in neurodegenerative diseases [100,101].”
Interstitial drug delivery system: Physiological basis and (pre)clinical progress
Zhao, A., Tang, Y., Shi, X., & Fan, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114275 · Cited by 1
Bobok, N., & Halushko, O. A. (2025) · Problems of ageing and longevity (Ukraine) · doi:10.71012/pro-ageing-2025-4-05 · Cited by 1
Sipos, S., Jerkić, M., Rotstein, O. D., & Schweizer, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010045 · Cited by 1
Lee, J., Park, D. G., & Sung, J. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00815 · Cited by 1
“Notably, GLP-1RAs demonstrated beneficial effects in phase 2 clinical trials for PD [4,5].”
“Unfolding Parkinson’s Disease Through the Microbiome-Gut-Brain Axis”
Shenthilvel, R. K., Thangavelu, A. U., Uvarajan, D., Mathuraj, M., & Ravikumar, M. (2026) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02462-0 · Cited by 1
“Evolving distinction between “gut-first” and ‘brain-gut” PD subtypes highlights the importance of developing subtype-specific neuroprotective and anti-inflammatory effects (Athauda et al. 2017, 2019; Athauda and Foltynie 2016 ; Hölscher 2014).”
Helal, M. M., Almosilhy, N. A., Abo‐elnour, D. E., Jaffal, R., Allam, E. G., Almosilhy, M. A., Batarseh, S. F., & Meshref, M. M. (2026) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2026.2627901 · Cited by 2
“However, inconsistencies have also been reported, especially regarding their effects on motor deterioration (157,235,274,275).”
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Uhrenholt, N. G., Ganeshalingam, A. A., Arnfred, S., Gæde, P., Pedersen, A. K., Larsen, P. V., Frystyk, J., & Bilenberg, N. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.02.009 · Cited by 2
Akintayo, C. O., Onyekweli, S. O., Omoruyi, G. O., & Akintayo, J. O. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-7437-6.ch013 · Cited by 1
Yelleswarapu, N. K., & Sidiropoulos, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062560 · Cited by 1
“Clinical trials with exenatide have shown modest improvements in motor and cognitive symptoms [113–115].”
Levodopa Efficacy and GLP ‐1 Receptor Agonists
Martinez, C., Girges, C., Foltynie, T., & Wills, A.-M. A. (2026) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70591 · Cited by 1
Self-citationCombination Disease‐Modifying Therapy for Neurodegenerative Diseases Using Repurposed Drugs
Shtilbans, A., & Lang, A. E. (2026) · Annals of Neurology · doi:10.1002/ana.78190 · Cited by 1
“61 Interestingly, risvodetinib suppressed c-Abl activation to baseline and substantially protected dopaminergic neurons from degeneration in mouse models of hereditary and sporadic PD. 106 It was tolerated in a recent phase 1 clinical trial in patients with PD. 63”
InfluentialGlucagon-like peptide-1 receptor agonists across anti-inflammation
Chen, D. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101474 · Cited by 1
The neuro-metabolic epidemic and the CB1R paradox
Vaccaro, F., Malta, G., Rizzo, M., Plescia, F., & Lavanco, G. (2026) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2026.102631 · Cited by 1
Raheel, K., Sheybani, L., Biabani, N., See, Q. R., Delogu, A., Rosenzweig, J., Cvetković, Z., Leech, R., Grossman, N., Tahmasian, M., et al. (2026) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2026.102298 · Cited by 1
Elghanam, Y., & Kim, E. (2026) · Archives of Pharmacal Research · doi:10.1007/s12272-026-01615-y · Cited by 2
“Early exenatide trials reported clinically meaningful improvements in motor severity off-medication that persisted after washout (Aviles-Olmos et al. 2013; Athauda et al. 2017).”
InfluentialAnderson, B. J., Daele, D. J. V., Claussen, A. D., Tanenbaum, Z. G., & Owen, S. R. (2026) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894261450724 · Cited by 1
“6,67,68 Intranasal delivery systems are being explored for GLP-1, to assist with bypassing the blood-brain barrier to facilitate treatment of central nervous sys-tem pathology.”
Glucagon-like peptide-1 agonists in Parkinson’s disease: a meta-analysis
Abdallah, A. K., Harb, A., Mansour, A., Nasreldin, A., Hamdy, R., Hatem, N., Mosad, N., Hamouda, M., Hamouda, A., & Arumaithurai, K. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09238-3 · Cited by 1
“Phase 2 trials, such as the study by Athauda et al. [ 12 ], generated optimism by reporting sus - tained improvements in motor scores suggesting a neuropro - tective effect.”
InfluentialConsiderations on combination therapies for disease modification in Parkinson’s
Hughes, R. M., Pilcicka, A., Klee, T., Ducotterd, F., Mortiboys, H., & Stott, S. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01483-9 · Cited by 1
“There are instances in which Phase 2 results offered encouraging initial signs of ef fi cacy,onlytobefollowedbydisappointingPhase3data,forexamplewith the exenatide trials 18,19 .”
Thome, A. D., Wang, J., Faridar, A., Zhao, W., Saetzler, V., Beers, D. R., & Appel, S. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177855 · Cited by 1
REPURPOSING DIABETES DRUGS FOR NEURODEGENERATIVE DISEASES: ANTI-DIABETIC DRUG REPOSITION
Parmar, M., & Panchal, S. S. (2019) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.0912297 · Cited by 1
Rehman, H. U., Kaleemullah, & Tareen, A. M. (2020) · International Journal of Research -GRANTHAALAYAH · doi:10.29121/granthaalayah.v7.i12.2019.320 · Cited by 1
“However, the other GLP-1 receptor agonists have insufficient response data as in term of “to penetrate the blood brain barrier” to favor the use of Liraglutide, Semaglutide or Lixisenatide (Athauda et al., 2017).”
BackgroundWyse, R. K. H., Cooper, A. A., & Stott, S. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839163401-00024 · Cited by 1
Eficácia terapêutica do exenatide no tratamento da doença de Parkinson
Alcântara, A. L. D. L. N., Cardoso, A. L. F. B., Pereira, M. I. P., de Aquino, D. S. A., & Mayer, A. B. (2023) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v22i2.52661 · Cited by 1
Troshneva, A. Y., & As, A. (2023) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-023-01488-4 · Cited by 1
“Three more clinical trials are currently ongoing in patients with PD: lixisenatide (clinical trial identi fi er NCT03439943), liraglutide (NCT02953665), and semaglutide (NCT03659682) [11, 18, 95].”
BackgroundCan venoms be used in neuroprotection?
Gazerani, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00003-8 · Cited by 1
Floresta, G., Arillotta, D., Catalani, V., Pelletier, G. D. P., Corkery, J., Guirguis, A., & Schifano, F. (2024) · Scientia Pharmaceutica · doi:10.3390/scipharm92020017 · Cited by 1
“This may occur because GLP-1 mimetics show pro-dopaminergic efficacy [49], and as a result can modulate reward [50].”
BackgroundCellular Adaptations to Intermittent Fasting with Emphasis on the Brain
Mattson, M. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-49622-6_7 · Cited by 2
Wang, Q., Liu, F., Wang, X., Zhong, L., Cai, B., & Chen, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-70758-z · Cited by 1
“…currently being tested include the glucagon-like peptide-1 receptor agonists exenatide and lixisenatide, which are commonly used to treat diabetes 13,14 ; deferiprone for transfusion-dependent thalassemia 15 ; inosine, a urate precursor and potential antioxidant 16 ; the tyrosine kinase…”
BackgroundGLP-1 Agonists for Weight Loss and Beyond
Quinter, C., Motilall, H., & Maberry, K. (2024) · Transformative Medicine · doi:10.54299/tmed/curq6915
Liu, W.-H., Liu, C., Xue, Y., Sun, X., Chen, X., & Chen, L. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1529919 · Cited by 2
Revisiting Parkinson’s Disease Treatment: Exploring Established Medications and Emerging Therapies
Brooks, D., Carter, A., Moore, E., & Grant, O. (2024) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/i340840675 · Cited by 1
Movement disorders in 2018: tackling this evil at the roots
Vidailhet, M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30464-2 · Cited by 1
Type 2 diabetes and Parkinson's disease
Shaw, K. (2019) · Practical Diabetes · doi:10.1002/pdi.2227 · Cited by 1
Treatment of Parkinson’s Disease: Early, Late, and Combined
Beudel, M., de Bie, R. M. A., & Leenders, K. L. (2019) · Springer eBooks · doi:10.1007/978-3-319-56015-1_288-1 · Cited by 1
GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact
Breder, I. S. S., & Sposito, A. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_51 · Cited by 1
Hay, K. R., Kukreti, N., Trujillo, P., Lin, Y., Kang, H., & Claassen, D. O. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-021-00387-8 · Cited by 1
Applications in medicine: mental health
Janssens, Y., Wynendaele, E., Audenaert, K., & Spiegeleer, B. M. J. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821389-6.00020-0 · Cited by 1
Epigenetics and regenerative medicine
Ehnes, D. D., Levy, S., & Ruohola‐Baker, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00019-0 · Cited by 1
DIABETES MELLITUS AND COVID-19. FEATURES OF THE MUTUAL INFLUENCE OF THE TWO PANDEMICS
KOVALENKO, J. S., La, I., Владимировна, К. И., & BIZHEVA, T. V. (2021) · The Bulletin of Contemporary Clinical Medicine · doi:10.20969/vskm.2021.14(4).58-66 · Cited by 1
GLP-1 receptor agonists for Parkinson's disease
Mulvaney, C. A., Duarte, G. S., Menon, S., Handley, J. D., & Emsley, H. C. A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012990 · Cited by 1
A Mendelian randomization study of glycemic and anthropometric traits and Parkinson’s diseasePreprint
Grover, S., Graf, R., Klein, C., Bruggemann, N., König, I., M, F. D. G., & Sharma, M. (2020) · bioRxiv · doi:10.1101/2020.03.31.017566 · Cited by 1
Sweet as Parkinson's disease: Rethinking the impact of diabetes mellitus
Cerasa, A., & Pagano, G. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.10.018 · Cited by 1
Insulin-releasing or insulin-sensitizing drugs in Parkinson's disease? Choosing a pathway
Sánchez‐Gómez, A., Compta, Y., & Martı́, M. J. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.10.017 · Cited by 1
Chiappini, S., Vickers‐Smith, R., Harris, D. R., Papanti, D., Corkery, J., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Preprints.org · doi:10.20944/preprints202309.1300.v1
Diabetes drug slows development of Parkinson’s disease
Adam, D. (2024) · Nature · doi:10.1038/d41586-024-00974-0 · Cited by 1
Semaglutide Ameliorates Neuroinflammation Caused by Enterogenous Pyrogen in APP/PS1 MicePreprint
Yuan, Y., Zhang, J., Zhang, Z., Zhai, Y., Cheng, X., Xue, L., Zhao, F. L., Cao, L. H., & Wang, H. (2025) · Research Square · doi:10.21203/rs.3.rs-6098406/v1 · Cited by 1
Advances in Disease Modifying Therapies for Parkinson's Disease
Hassanzadeh, K., & Mouradian, M. M. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch2 · Cited by 1
Is Exenatide Neuroprotective in Parkinson Disease
Okun, M. S. (2017) · Journal watch · doi:10.1056/nejm-jw.na44767
Verbessert Exenatid Motorikstörungen?
Reichmann, H. (2017) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-017-2332-9
Diabetesmedisin mot Parkinsons sykdom
Sivertsen, Ø. S. (2017) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0931
“Diabetesmedisin mot Parkinsons sykdom | Tidsskrift for Den norske legeforening symptomatisk effekt og en mulig nevroprotektiv virkning hos pasienter med Parkinsons sykdom (1).”
BackgroundUpdate Pharmakotherapie bei Parkinson
Ceballos-Baumann, A., & Fietzek, U. M. (2018) · Nervenheilkunde · doi:10.1055/s-0038-1641240
“Das Ergebnis der Vorgängerstudie im Sinne einer Verbesserung des UPDRS motor scores in der Off-Bedingung um 1,0 Punkt wird repliziert, die Placebogruppe verschlechtert sich um 2,1 Punkte (p < 0,05) (55).”
BackgroundMechanisms of diabetes and dementia
Puttanna, A. (2019) · Practical Diabetes · doi:10.1002/pdi.2234
Corvol, J. (2019) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2019.11.012
Pan-organ model integration of metabolic and regulatory processes in type 1 diabetesPreprint
Guebila, M. B., & Thiele, I. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/859876
“Furthermore, a clinical trial has repurposed Exenatide, a glucagon-like peptide-1 (GLP-1), in the treatment of PD (Athauda et al., 2017; Aviles-Olmos et al., 2013; Aviles-Olmos et al., 2014).”
BackgroundPick the Company 企業紹介(第76回 2)株式会社TV・ポータル
平田, 和., & 武居, 邦. (2010) · 衛星&ケーブルテレビ
Parkinson's Disease Detection with Ensemble Architectures based on ILSVRC ModelsPreprint
Mostafa, T. A., & Cheng, I. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.12496 · Cited by 4
“There are also new forms of treatment like Exenatide [7], which show promising results with cases where PD was detected in the initial stages.”
BackgroundLi, Z., Chen, X., Vong, J. S. L., Zhao, L., Huang, J., Yan, L. Y. C., Ip, B. Y. M., Wing, Y. K., Lai, H. M., Mok, V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.21.423879
Dramatic Results from an Obesity Drug May Point Toward Multiple Uses in Neurology
Robinson, R. (2021) · Neurology Today · doi:10.1097/01.nt.0000742020.38028.1d
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Can a Type-2 Diabetes Mellitus drug be hope for Multiple System Atrophy?
Demir, Y. (2020) · Advances in Clinical Neuroscience & Rehabilitation · doi:10.47795/rlyy2780
Reply to: “ HbA1c and Motor Outcome in Parkinson's Disease in the Mark‐PD Study”
Markaki, I., Ntetsika, T., & Svenningsson, P. (2021) · Movement Disorders · doi:10.1002/mds.28676
Image Prior Transfer and Ensemble Architectures for Parkinson’s Disease Detection
Mostafa, T. A., & Cheng, I. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-90439-5_5
Alimentos infantiles para el periodo lácteo: parte I
Berruezo, G. F. R. (2009) · ANS. Alimentación, nutrición y salud
Grotta, L. D., DeMarco, S., & Leman, K. (2021) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001514
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20
Advances in Biological and Clinical Research of GLP-1 Receptor Agonists
李, 鑫. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124430
Söderbom, G., ESTERLINE, R. L., Oscarsson, J., & Mattson, M. P. (2020) · International review of neurobiology · doi:10.1016/s0074-7742(20)30134-3
Past・Present・Future on Parkinson's Disease Therapeutics
Hattori, N. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.762
Diabète, Parkinson même combat ?
Y.-M., D. (2017) · Option/Bio · doi:10.1016/s0992-5945(17)30260-x
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
A negative effect of poorly controlled diabetes mellitus on the treatment of Parkinson’s disease
Lee, J.-J., Hong, J. Y., & Baik, J. S. (2022) · Neurology Asia · doi:10.54029/2022vsp
Traitement médicamenteux de la maladie de Parkinson
Delamarre, A., Meissner, W. G., Erraud, J., & Tison, F. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-76331-1.00023-9
Lebensstil und Parkinson-Risiko
Eschle, D. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00174-z
“Von den 62 eingeschlossenen iPSPatienten/-innen wurden 31 in der Verum- und 29 in der Placebogruppe nach 60 Wochen ausgewertet.”
BackgroundInfluentialAnalysis of LIN28A variants in patients with Parkinson’s disease
Peng, H., Li, Y., Yoshino, H., Shimizu, M., Nishioka, K., Funayama, M., & Hattori, N. (2023) · Journal of Human Genetics · doi:10.1038/s10038-022-01109-x
“these findings suggest the efficacy of GLP-1 inhibitors as PD treatments [14, 15].”
BackgroundSelf-citationEffects of Metabolic Syndrome on Parkinson’s Disease and Nutraceutical Intervention Strategies
Komuro, J. E., dos Santos, D. F. B., Schelp, A. B., Papini, S. J., & Schelp, A. O. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.108956
Novel disease-modifying treatments for synucleinopathies
Singer, W., Palma, J., Kaufmann, H., & Low, P. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85492-4.00110-1
Circadian Rhythmicity in Aging and Parkinson’s Disease
Jyothi, H. J., Bhaduri, B., Hingmire, M., Verma, P., Yasha, T. C., & Alladi, P. A. (2023) · Healthy ageing and longevity · doi:10.1007/978-3-031-22468-3_12
Neuroprotective potential of incretinomimetics
Kokin, A. S., Суплотова, Л. А., Сергеевна, Д. Т., & Makarova, O. B. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-159
ANÁLOGOS DO GLP-1 E NEUROPROTEÇÃO: UMA REVISÃO SISTEMÁTICA
Castro, J. V., da Cruz, T. B. F., Fonseca, I. O., & Tostes, G. C. U. (2023) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2023v5n4p2727-2740
Polypharmazie bei der Behandlung von Parkinsonsymptomen: eine Nutzen-Risiko Abwägung
Bedarf, J. R., Csóti, I., Herbst, H., Urban, P. P., Woitalla, D., & Wüllner, U. (2023) · DGNeurologie · doi:10.1007/s42451-023-00598-0
Quarde, A. (2023) · doi:10.1002/9781119863564.ch4
Pleiotropic Benefits with Glucagon-like Peptide-1 Receptor Agonists: A Clinical Review
PATANGE, S. A., Singh, S. K., Bhattacharyya, S., Jagadeesha, A., Bhartia, M., Aneja, P., Hendral, A., & Chaudhuri, S. R. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_19_23
Antidiabetikum auf dem Prüfstand
Deuschl, G. (2024) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-024-3876-0
A GLP-1 Receptor Agonist Looks Promising in Phase 2 Study for Parkinson's Disease
Talan, J. (2024) · Neurology Today · doi:10.1097/01.nt.0001017612.54350.b4
Increased dementia risk in patients with Parkinson’s disease attributed to metabolic syndrome
Tur, E. K., Kutlu, H., Sever, N., Arı, B. Ç., & Gözke, E. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07803-2
“Additionally, GLP-1 receptor agonists activate the PI3K/Akt pathway through engagement with the GLP-1 receptor, influencing down - stream components of the insulin signaling pathway and providing neuroprotective effects [ 35, 36 ].”
Courtman, M., Thurston, M., Wang, H., Banerjee, S., Streeter, A., McGavin, L., Hall, S., Sun, L., Ifeachor, E., & Mullin, S. (2024) · medRxiv · doi:10.1101/2024.11.21.24317644
Precision mitochondrial medicine: Uncovering pathways across diverse diseases
Sainero‐Alcolado, L., Garde-Lapido, E., Liaño-Pons, J., & Arsenian‐Henriksson, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-98808-7.00007-2
Pipeline of Pharmacotherapy in Parkinson’s Disease
Brugger, F., & Hägele-Link, S. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108989855.026
Amanat, M., Tandon, S., & Singh, R. (2025) · Current Diabetes Reviews · doi:10.2174/0115733998341202241202103725
Metadata
- Authors
- Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., Li, Y., Aviles-Olmos, I., Warner, T. T., Limousin, P., Lees, A. J., Greig, N. H., Tebbs, S., & Foltynie, T.
- Affiliations
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- National Institute on Aging (US)
- Corresponding author
- Foltynie, Thomas
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 390
- Issue
- 10103
- Pages
- 1664-1675
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC5831666
- OpenAlex
- W2744843428
- Cited by
- 889
- References
- 38
- Citations by year
- 2026: 114 · 2025: 136 · 2024: 114 · 2023: 73 · 2022: 85 · 2021: 93 · 2020: 98 · 2019: 77 · 2018: 77 · 2017: 20
- FWCI
- 51.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Research (University of Surrey) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- National Institutes of Health (Z99 AG999999)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, exenatide, GLP-1 receptor agonists, neuroprotection, motor symptoms, off-medication state, dopaminergic therapy, neurodegeneration, adverse events, injection site reactions, gastrointestinal symptoms, drug repurposing, disease-modifying therapy
- MeSH terms
- Exenatide, Adult, Aged, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neurologic Examination, Parkinson Disease, Peptides, Venoms, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
